Diabetes Mellitus and Oral Hypoglycaemic Drugs

Classification

Insulin(below). Sulfonylureas: glibenclamide, glimepiride, gliclazide. Meglitinides: repaglinide, nateglinide. Biguanide: metformin. TZDs: pioglitazone. α-glucosidase inhibitors: acarbose. DPP-4 inhibitors: sitagliptin, vildagliptin. GLP-1 agonists: exenatide, liraglutide, semaglutide. SGLT2 inhibitors: dapagliflozin, empagliflozin, canagliflozin.

Insulin (classified by ONSET/DURATION, not structure)

Rapid(lispro, aspart, glulisine): onset~~15min, duration 3-4h — altered sequence reduces hexamer self-association(bypasses dissociation rate-limiting step) → mealtime/prandial, given right before eating. Short(regular): onset~~30min, duration 6-8h — still hexameric, slower → given 30min before meals. Intermediate(NPH): onset~2h, duration 12-18h — protamine-complexed suspension, tissue protease degradation delays release(formulation-based, distinct from structural-modification approach). Long(glargine, detemir, degludec): onset 1-2h, duration 20-42h(degludec longest), FLAT peakless profile — glargine precipitates at physiological pH after injection(soluble at acidic formulation pH) → slow-dissolving depot → steady basal coverage, no hypoglycaemia-risk peak.

Basal-bolus(long-acting once/twice daily + rapid-acting per meal) = reproduces normal physiological secretion(continuous basal+meal spikes) better than old premixed regimens.

Oral/Injectable Agents — Mechanism

Sulfonylureas: bind SUR1 subunit of β-cell K-ATP channel → closes channel INDEPENDENT of normal glucose-sensing/ATP step → depolarize→Ca2+ influx→insulin release(same final step, pharmacological not physiological trigger). REQUIRES functioning β-cells(ineffective type 1). GLUCOSE-INDEPENDENT → genuine HYPOGLYCAEMIA risk.

Meglitinides: SAME SUR1/K-ATP site, faster onset/shorter duration — with-meal dosing → rapid transient burst matched to meal load → ↓(not eliminate) between-meal hypoglycaemia vs sulfonylureas.

Metformin: activates AMPK in hepatocytes(energy-sensing) → suppresses hepatic gluconeogenesis(dominant mechanism) + modest ↑peripheral insulin sensitivity. Does NOT stimulate insulin release → essentially NO hypoglycaemia risk as monotherapy → 1st-line initial Rx across guidelines. Lactic acidosis(rare, serious) — gluconeogenesis pathway also clears lactate, blocking it ↑lactate accumulation risk, AMPLIFIED by renal impairment(renally cleared) → CI/dose-adjust in significant renal impairment + hold around iodinated contrast(AKI risk could precipitate accumulation).

TZDs(pioglitazone): activate nuclear receptor PPAR-γ → gene transcription in adipose/muscle/liver → ↑insulin sensitivity. DIFFERENT mechanism class(nuclear receptor vs channel/enzyme) → SLOW onset(weeks). SE follows PPAR-γ’s adipocyte role: fluid retention/oedema+HF exacerbation(CI significant HF) + weight gain(adipogenic) + ↑fracture risk(bone remodelling) + debated bladder cancer signal.

α-glucosidase inhibitors(acarbose): inhibit intestinal α-glucosidase → ↓carb breakdown/absorption → blunts postprandial spike. Acts IN GUT LUMEN(minimal systemic absorption) → NO hypoglycaemia monotherapy but POOR tolerability(flatulence, bloating, diarrhoea — undigested carb reaching colon, bacterial fermentation) limits practical use.

DPP-4 inhibitors: inhibit DPP-4(normally degrades endogenous incretins GLP-1+GIP) → preserves incretin levels → GLUCOSE-DEPENDENT ↑insulin release(active mainly when glucose already elevated, mirrors incretins’ own physiology) → LOW hypoglycaemia risk despite ↑insulin — DISTINCT from sulfonylurea’s glucose-independent mechanism.

GLP-1 agonists: DIRECTLY activate GLP-1 receptor(stronger than DPP-4’s endogenous-preservation approach) — same glucose-dependent logic PLUS separate effects: delayed gastric emptying(GI SE + extra postprandial blunting) + central appetite suppression(genuine weight-loss effect → dual diabetes+obesity use, semaglutide prominent). Pancreatitis = specific rare risk.

SGLT2 inhibitors: inhibit SGLT2(renal proximal tubule, majority of filtered glucose reabsorption) → glucose excreted in urine, INSULIN-INDEPENDENT mechanism(works even with substantial β-cell failure). Genuine CV+renal protective benefits beyond glucose-lowering(↓HF hospitalization, slowed diabetic kidney disease — mechanisms still characterized, natriuresis/volume+renal haemodynamic theories). SE: genital mycotic infections+UTIs(glucose-rich urine=growth substrate) + EUGLYCAEMIC DKA(HIGH-YIELD, easily missed — DKA at only mildly elevated/near-normal glucose, since mechanism doesn’t need severe hyperglycaemia → glucose-level-alone reliance dangerously misleading).

Clinical Relevance

Hypoglycaemia-risk distinction = single most load-bearing organizing fact: GLUCOSE-INDEPENDENT secretagogues(sulfonylureas, meglitinides) = genuine risk vs GLUCOSE-DEPENDENT mechanisms(metformin, DPP-4i, GLP-1 agonists, SGLT2i — none stimulate insulin release glucose-independently) = minimal risk monotherapy. Directly explains WHY metformin=1st-line + why combination regimens increasingly favour newer lower-risk classes as add-on over older secretagogues where cost/access allow.

Classification

Insulin (all types — covered in detail below)
Sulfonylureas: glibenclamide (glyburide), glimepiride, gliclazide
Meglitinides: repaglinide, nateglinide
Biguanides: metformin
Thiazolidinediones (TZDs): pioglitazone
α-glucosidase inhibitors: acarbose
DPP-4 inhibitors (gliptins): sitagliptin, vildagliptin
GLP-1 receptor agonists: exenatide, liraglutide, semaglutide
SGLT2 inhibitors: dapagliflozin, empagliflozin, canagliflozin

Insulin

Insulin preparations are classified by onset and duration of action, not by chemical structure alone, since this pharmacokinetic profile is what actually determines clinical use:

Rapid-acting (lispro, aspart, glulisine): onset ~15 minutes, duration 3–4 hours — engineered by altering amino acid sequence to reduce insulin’s normal tendency to self-associate into hexamers (native insulin hexamers must dissociate to monomers before absorption, a rate-limiting step these analogues bypass), used for mealtime (prandial) coverage given directly before eating.
Short-acting (regular): onset ~30 minutes, duration 6–8 hours — still hexameric, slower than the rapid-acting analogues, given 30 minutes before meals to allow time for dissociation/absorption.
Intermediate-acting (NPH): onset ~2 hours, duration 12–18 hours — a protamine-complexed suspension, absorption slowed by the need for tissue proteases to degrade the protamine complex before insulin release, a formulation-based delay mechanism distinct from the rapid-acting analogues’ structural modification approach.
Long-acting (glargine, detemir, degludec): onset 1–2 hours, duration 20–42 hours (degludec longest), engineered for a relatively flat, peakless profile — glargine precipitates at physiological pH after subcutaneous injection (soluble at its acidic formulation pH, forming a slow-dissolving depot at tissue pH), providing steady basal coverage without the pronounced peak that would risk hypoglycaemia between meals.

Basal-bolus regimens (long-acting insulin once/twice daily plus rapid-acting insulin with each meal) aim to reproduce normal physiological insulin secretion (a continuous low-level basal secretion plus meal-triggered spikes) more closely than older twice-daily premixed regimens — the specific rationale for why modern regimens layer these onset/duration profiles deliberately rather than using a single insulin type.

Oral/Injectable Hypoglycaemic Agents — Mechanism

Sulfonylureas: bind the SUR1 subunit of the pancreatic β-cell ATP-sensitive K⁺ channel, closing the channel independent of the normal glucose-sensing/ATP-generation step — this depolarizes the β-cell, opens voltage-gated Ca²⁺ channels, and triggers insulin release, the identical final channel-closure step normal glucose metabolism would trigger, but achieved pharmacologically rather than physiologically — meaning sulfonylureas require functioning β-cells (ineffective in type 1 diabetes, where β-cells are destroyed) and carry a genuine, mechanism-predictable hypoglycaemia risk (insulin release is stimulated regardless of actual blood glucose level, unlike the physiological glucose-sensing process it bypasses).

Meglitinides (repaglinide): act at the same SUR1/K-ATP channel site as sulfonylureas but with much faster onset and shorter duration — taken specifically with meals for a rapid, transient insulin-release burst matched to that meal’s glucose load, reducing (though not eliminating) the between-meal hypoglycaemia risk that sulfonylureas’ longer action carries.

Metformin (biguanide): activates AMP-activated protein kinase (AMPK) in hepatocytes, the cell’s principal energy-sensing pathway, which suppresses hepatic gluconeogenesis (metformin’s dominant mechanism of glucose-lowering) and modestly increases peripheral insulin sensitivity/glucose uptake — critically, metformin does not stimulate insulin release at all, meaning it carries essentially no hypoglycaemia risk as monotherapy, a specific, high-yield distinguishing safety feature from the insulin-secretagogue classes above, and the reason metformin remains first-line initial therapy for type 2 diabetes across essentially all major guidelines. Lactic acidosis is metformin’s rare but serious, specifically-examined risk — related to its inhibition of hepatic gluconeogenesis, a pathway that also normally clears lactate, and this risk is specifically amplified by renal impairment (metformin is renally cleared, and accumulation raises lactic acidosis risk), the mechanistic reason metformin is contraindicated/dose-adjusted in significant renal impairment and temporarily withheld before/after iodinated contrast administration (acute kidney injury risk from contrast could precipitate metformin accumulation).

Thiazolidinediones (pioglitazone): activate the nuclear receptor PPAR-γ (peroxisome proliferator-activated receptor gamma), altering gene transcription in adipose tissue, muscle, and liver to increase insulin sensitivity — a genuinely different mechanism from every class above (nuclear receptor/gene transcription rather than ion channel or enzyme-activity modulation), with a correspondingly slow onset of effect (weeks) reflecting this transcriptional mechanism. Adverse effects directly follow from PPAR-γ’s role in adipocyte differentiation/fluid handling: fluid retention/oedema and heart failure exacerbation (a specific contraindication in significant heart failure) and weight gain (genuine adipogenic effect), plus an increased fracture risk (a specific, examined effect on bone remodelling) and a historically-flagged, still-debated bladder cancer signal with pioglitazone specifically.

α-glucosidase inhibitors (acarbose): inhibit intestinal brush-border α-glucosidase enzymes, slowing carbohydrate breakdown/absorption and blunting the postprandial glucose spike — acting entirely within the gut lumen (minimal systemic absorption), meaning no hypoglycaemia risk as monotherapy, but a genuinely poor tolerability profile (flatulence, bloating, diarrhoea — the direct consequence of undigested carbohydrate reaching the colon and being fermented by colonic bacteria) limits its practical use despite this mechanism-based safety advantage.

DPP-4 inhibitors (sitagliptin): inhibit dipeptidyl peptidase-4, the enzyme that normally rapidly degrades endogenous incretin hormones (GLP-1 and GIP, released from the gut in response to a meal, which normally augment glucose-dependent insulin release and suppress glucagon) — by preserving endogenous incretin levels, DPP-4 inhibitors produce a glucose-dependent enhancement of insulin release (active mainly when glucose is already elevated, mirroring the incretins’ own physiological glucose-dependence), a specific, mechanism-driven reason this class carries low hypoglycaemia risk despite ultimately increasing insulin release, genuinely distinct from sulfonylureas’ glucose-independent mechanism.

GLP-1 receptor agonists (liraglutide, semaglutide): directly activate the GLP-1 receptor (bypassing the need to preserve endogenous incretin, and achieving a stronger effect than DPP-4 inhibition’s more modest endogenous-hormone-preservation approach) — same glucose-dependent insulin-release-enhancement/glucagon-suppression logic as above, plus genuinely separate, clinically significant effects: delayed gastric emptying (contributing to the class’s characteristic GI adverse effects, and to modest additional postprandial glucose blunting) and central appetite suppression (a genuine, exploited weight-loss effect, the basis for this class’s dual use in diabetes and, at higher doses, in obesity management specifically, semaglutide being the most prominent current example). Pancreatitis is a specific, examined, though relatively rare, risk associated with this class.

SGLT2 inhibitors (dapagliflozin, empagliflozin): inhibit the sodium-glucose cotransporter-2 in the renal proximal tubule, the transporter normally responsible for the majority of filtered glucose reabsorption — blocking it causes glucose (and, secondarily, some sodium) to be excreted in urine rather than reabsorbed, an insulin-independent glucose-lowering mechanism (working entirely at the kidney, unrelated to β-cell function or insulin sensitivity), meaning it remains effective even in advanced type 2 diabetes with substantial β-cell failure. Genuine, actively-studied cardiovascular and renal protective benefits beyond glucose lowering (reduced heart failure hospitalization and slowed progression of diabetic kidney disease, mechanisms still being actively characterized but thought to relate to the mild natriuresis/volume effects and possibly direct renal haemodynamic effects) have made this class increasingly prominent in current practice. Adverse effects: genital mycotic infections and urinary tract infections (a direct, predictable consequence of glucose-rich urine providing a favourable growth substrate for yeast/bacteria) and euglycaemic diabetic ketoacidosis (a specific, high-yield, easily-missed complication — DKA can occur with SGLT2 inhibitors at only mildly elevated or even near-normal glucose levels, since the mechanism doesn’t depend on severe hyperglycaemia the way typical DKA does, meaning a clinician relying on glucose level alone to rule out DKA can be dangerously misled in a patient on this drug class).

Clinical Relevance

The hypoglycaemia-risk distinction running through this entire topic — glucose-independent insulin secretagogues (sulfonylureas, meglitinides) carrying genuine risk versus glucose-dependent-mechanism drugs (metformin, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, none of which stimulate insulin release in a glucose-independent way) carrying minimal risk as monotherapy — is the single most clinically load-bearing organizing fact in modern type 2 diabetes pharmacotherapy, directly explaining both why metformin remains first-line and why combination regimens increasingly favour these newer, lower-hypoglycaemia-risk classes as add-on therapy over older secretagogues where cost/access allow the choice.

Pancreatic β-cell K-ATP channel/insulin release pathway with sulfonylurea/meglitinide bypass of normal glucose-sensing marked.
Insulin type onset/duration profiles (rapid, short, intermediate, long) plotted as time-action curves for a basal-bolus regimen.
Incretin pathway (GLP-1/GIP release → DPP-4 degradation) with DPP-4 inhibitor and GLP-1 agonist intervention points marked.